MarketPulse

monoclonal antibodies

5 articles
The Motley FoolThe Motley Fool··Seena Hassouna

ENAVATE's Zenas Stake Surge Masks Real Story: Obexelimab Pipeline

ENAVATE deepens Zenas BioPharma stake to $142.3M. Key catalyst: obexelimab Phase 2 lupus data and Q2 2026 FDA submission.
ZBIOFDA approvalautoimmune diseases
The Motley FoolThe Motley Fool··Seena Hassouna

Specialist Biotech Fund's $25.8M Spyre Bet Signals Confidence in Preclinical Pipeline

VR Adviser increased Spyre Therapeutics stake by 1M shares to $120.74M. Stock surged 132% annually, but preclinical risks remain high for retail investors.
SYREbiotech investmentmonoclonal antibodies
The Motley FoolThe Motley Fool··Jonathan Ponciano

Great Point Partners Doubles Down on Apogee Therapeutics With $28M Position

Great Point Partners expands Apogee Therapeutics stake to $28.23M, now its largest holding. Stock doubled in value; Phase 2 atopic dermatitis data expected mid-2026.
APGEbiotechclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Biopharmaceutical CMO Market Set to Quadruple to $76.2B by 2035

Biopharmaceutical CMO market to grow from $21.16B in 2025 to $76.2B by 2035, driven by outsourcing demand and capacity constraints.
TMOLZAGYWXXWYbiologicsmonoclonal antibodies
The Motley FoolThe Motley Fool··Jonathan Ponciano

Commodore Capital Expands Spyre Therapeutics Position as Stock Climbs 63% YoY

Commodore Capital increases Spyre Therapeutics stake to $78.24M as stock surges 63% YoY. Biotech firm has $757M cash and expects Phase 2 data in 2026.
ALKSSYRERLAYXENEbiotechbalance sheet strength